Form D · Biotechnology
Exacis Biotherapeutics Inc.
Cambridge, MA · CIK 0001844030
Offering snapshot reported Feb 4, 2021 · SEC filing
- Reported sold
- $50K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jan 22, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 4, 2021 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Feb 3, 2021 | Initial | $1,125,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-388374
Convertible Note
Source: Form D, filed Feb 4, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Angel | Director |
| Mark Corrigan | Director |
| Gregory Fiore | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1035 Cambridge Street Suite 17 B
Cambridge, MA, 02141
Cambridge, MA, 02141